Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD33 antibody-drug conjugate BL-M11D1

An antibody-drug conjugate (ADC) composed of gemtuzumab, an immunoglobulin G4 (IgG4) monoclonal antibody directed against the CD33 antigen, conjugated, via a cathepsin B-cleavable linker, to the camptothecin derivative and topoisomerase 1 inhibitor Ed-04, with potential antineoplastic activity. Upon administration of anti-CD33 ADC BL-M11D1, gemtuzumab specifically targets and binds to the cell surface antigen CD33 expressed on myeloid leukemia cells. Upon binding, internalization and linker cleavage, Ed-04 is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells that express CD33. Gemtuzumab may also induce an antibody-dependent cellular cytotoxicity (ADCC) against CD33-expressing tumor cells. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and myeloid leukemia cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD33 ADC BL-M11D1
Gemtuzumab/Ed-04 ADC BL-M11D1
Code name:BL M11D1
BL-M11D1
BLM11D1
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search